30 active not recruiting. 30 Phase 3, 3 Phase 2.
By phase and status
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Trials (filtered) newest first · largest first
All 30 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge
Antimalarial monoclonal antibodies, Dihydroartemisinin - Piperaquine (DP), Placebo mMAB - Malaria, Severe Malaria | Phase 3 | Active not recruiting | 398 | 2025-05-02 | 2026-08-05 |
Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
BCD-131 (pegdarbepoetin beta), Mircera (methoxypolyethylene glycol-epoetin beta) - Anemia, Chronic Kidney Disease | Phase 3 | Active not recruiting | 228 | 2025-03-01 | 2026-09-01 |
Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.
Roxadustat - Perioperative Anemia | Phase 3 | Active not recruiting | 158 | 2024-11-10 | 2025-01-13 |
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Roxadustat - Chronic Kidney Disease, Renal Anemia | Phase 3 | Active not recruiting | 98 | 2024-01-16 | 2026-10-13 |
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Luspatercept, Epoetin Alfa - Myelodysplastic Syndromes | Phase 3 | Active not recruiting | 402 | 2023-10-24 | 2026-06-30 |
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
Luspatercept - Myelodysplastic Syndromes | Phase 3 | Active not recruiting | 106 | 2023-10-05 | 2026-06-15 |
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Oral Azacitidine, Placebo for Oral Azacitidine - Myelodysplastic Syndromes | Phase 2 / Phase 3 | Active not recruiting | 230 | 2022-12-14 | 2026-02-25 |
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Danicopan - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | 80 | 2022-10-28 | 2026-06-18 |
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
Ravulizumab, Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | 202 | 2022-08-01 | 2026-04-30 |
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
Mitapivat, Mitapivat-matching placebo - Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | Phase 3 | Active not recruiting | 49 | 2022-06-08 | 2026-10-28 |
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
Mitapivat, Mitapivat-matching placebo - Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia | Phase 3 | Active not recruiting | 30 | 2022-06-06 | 2026-10-28 |
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
CTX001 - Beta-Thalassemia, Thalassemia | Phase 3 | Active not recruiting | 16 | 2022-05-03 | 2026-07-01 |
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
CTX001 - Sickle Cell Disease, Hydroxyurea Failure | Phase 3 | Active not recruiting | 13 | 2022-05-02 | 2026-07-01 |
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Mitapivat, Mitapivat-matching placebo - Sickle Cell Disease | Phase 2 / Phase 3 | Active not recruiting | 286 | 2022-02-11 | 2026-10-26 |
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | 41 | 2021-11-17 | 2026-10-01 |
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Crovalimab - Atypical Hemolytic Uremic Syndrome | Phase 3 | Active not recruiting | 83 | 2021-10-22 | 2026-10-30 |
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
Iptacopan - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | 208 | 2021-07-27 | 2026-08-07 |
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
Crovalimab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | 51 | 2021-03-17 | 2026-08-26 |
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACE-536, Placebo - Myeloproliferative Disorders, Myelofibrosis | Phase 3 | Active not recruiting | 313 | 2021-02-25 | 2026-07-16 |
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Etavopivat Tablets Low dose, Etavopivat Tablets High dose, Placebo Tablets - Sickle Cell Disease | Phase 3 | Active not recruiting | 450 | 2021-01-29 | 2026-04-06 |
Showing 20 of 30. Sign in to see all of them.
Narrower conditions
Hematologic Diseases (7) · Anemia, Sickle Cell (6) · Hemoglobinuria, Paroxysmal (6) · Myelodysplastic Syndromes (5) · Hemoglobinopathies (3) · Atypical Hemolytic Uremic Syndrome (2) · Genetic Diseases, Inborn (2) · Hemolysis (2) · Metabolic Diseases (2) · Primary Myelofibrosis (2) · Pyruvate Kinase Deficiency of Red Cells (2) · Renal Insufficiency, Chronic (2) · Sickle Cell Trait (2) · Vaso-Occlusive Crises (2)
Broader conditions
Hemic and Lymphatic Diseases (30) · Hematologic Diseases (23) · Anemia, Hemolytic (14) · Bone Marrow Diseases (12) · Anemia, Hemolytic, Congenital (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Pathological Conditions, Signs and Symptoms (7) · Myelodysplastic Syndromes (6) · Pathologic Processes (6) · Genetic Diseases, Inborn (5) · Chronic Disease (4) · Disease Attributes (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4)
Interventions
luspatercept (4) · Epoetin Alfa (3) · eculizumab (3) · mitapivat (3) · exagamglogene autotemcel (2) · roxadustat (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Adrenal Cortex Hormones (1) · Azacitidine (1) · Biopsy (1) · CT-P10 (1) · Cyclophosphamide (1) · Danazol (1) · Erythrocyte Count (1) · Excipients (1)
Sponsors
Hoffmann-La Roche (5) · Agios Pharmaceuticals, Inc. (3) · Bristol-Myers Squibb (3) · Celgene (2) · National Cancer Institute (NCI) (2) · Novartis Pharmaceuticals (2) · Vertex Pharmaceuticals Incorporated (2) · Alexion Pharmaceuticals, Inc. (1) · Astellas Pharma Global Development, Inc. (1) · Biocad (1) · Centre For International Health (1) · Forma Therapeutics, Inc. (1) · Genetix Biotherapeutics Inc. (1) · Liverpool School of Tropical Medicine (1) · Regeneron Pharmaceuticals (1)
Countries
United States (23) · France (17) · Germany (17) · Italy (17) · Spain (17) · Canada (15) · United Kingdom (15) · Poland (13) · Brazil (12) · Greece (11) · Japan (11) · Turkey (Türkiye) (11) · China (10) · Czechia (10) · Belgium (9)
Top investigators
Amit K Verma (1) · Anjulika Chawla, MD, FAAP (1) · Darrell Triulzi, MD (1) · Feiko O Ter Kuile, MD, PhD (1) · Laxman Shestha, MD (1) · Maria Brooks, PhD (1) · Mark Gladwin, MD (1) · Min Yan, MD, PhD (1)
Results publications
PMID 37254256, PMID 39535306, PMID 33439748, PMID 40978458, PMID 42274009, PMID 28851784, PMID 31365801, PMID 33232476, PMID 34865212, PMID 35019238, PMID 35427411, PMID 37031691, PMID 37311468, PMID 37421604, PMID 37801678, PMID 37934880, PMID 38884175, PMID 38924124, PMID 39038479, PMID 39644907, PMID 40088922, PMID 40377899, PMID 40569673, PMID 40694294, PMID 41461260, PMID 41493372, PMID 41549790, PMID 41809202, PMID 42287326, PMID 42456844, PMID 42913682
NIH funding
2023 (6), U10CA021115 (2), U10CA180820 (2), U24CA196172 (2), 2017 (1), 2019 (1), R01CA193541 (1), U01GH002290 (1), UG3HL143192 (1)